Cholelithiasis
Conditions
Keywords
Cholelithiasis, biliary, cholecystostomy, laparoscopic, cholecystectomy, gallstones
Brief summary
In this new era of less invasive procedures, the indications for endoscopic ultrasound (EUS)-guided gallbladder drainage (GBD) are rapidly expanding. Nowadays, the standard treatment for uncomplicated cholelithiasis (symptomatic patients not requiring hospital admission or non-surgically managed during one or more hospital admissions) is elective laparoscopic cholecystectomy. To avoid the complications, difficulties and disadvantages of cholecystectomy, the investigators proposed a single-center study to determine the safety and effectiveness of EUS-guided GBD with electrocautery-enhanced lumen-apposing metal stent (LAMS) (Boston Scientific, Marlborough, MA, EEUU) with stone removal in patients with cholelithiasis, in comparison with the gold standard treatment, the elective laparoscopic cholecystectomy.
Detailed description
Currently, elective laparoscopic cholecystectomy (LC), is the preferred management for cholelithiasis in patients with history of gallstones-related adverse events, increased risk for gallbladder cancer, or recurrent typical biliary colic. Although elective LC is a commonly performed surgery, the incidence of serious adverse events is around 2.6%. Also, post-cholecystectomy syndrome, alkaline reflux gastritis and bile duct injury are chronic and feared adverse events secondary to gallbladder removal. To avoid them, a more conservative approach need to be address. The preservation of the gallbladder permits the conservation of its physiological functions, preventing LC adverse events, with potential less recovery time. In this scenario, the endoscopic ultrasound (EUS) with lumen-apposing metal stent (LAMS)-assisted cholecystostomy for gallstones clearance has gained popularity due its trend toward an improved safety profile. The increased on advanced endoscopy experience along with the development of new stents, tools, and delivery systems, had placed the EUS-guided cholecystostomy as a plausible alternative to elective LC for acute cholecystitis, high-risk surgical patients, or patients with a concomitant bile duct neoplasia. In those contexts, EUS-guided cholecystostomy has demonstrated similar or even less hospitalization length of stays, adverse events, readmissions and reinterventions in comparison with elective LC or percutaneous drainage, respectively. Thus, the feasibility of EUS-guided cholecystostomy for cholelithiasis deserves to be explored. This study pursues to compare between the effectiveness and safety of EUS-guided cholecystostomy and the elective laparoscopic cholecystectomy through an interventional, two group assignment, controlled trial.
Interventions
PROCEDURELAMS placement for cholecystostomy
The EUS-guided cholecystostomy entails placing a 10 mm x 10 mm or 10mm x 15mm Electrocautery-Enhanced LAMS for direct cholecystoscopy with a transnasal gastroscope. Then, the cholecystostomy will be performed with an echoendoscope, assisted by fluoroscopy to allow the puncturing of the gallbladder form either the duodenal bulb (cholecysto-duodenoscopy) or the gastric antrum (cholecysto-gastrostomy). Subsequently, from the most optimal anatomic point it will be tutored with a 10mmx10mm or 10mm x 15mm LAMS to create anastomosis between the structures. Then, the stone clearance will be performed by endoscopy (basket catheters) or by cholangioscopy (mechanical lithotripsy with or without basket catheters).
PROCEDURELaparoscopic cholecystectomy
A laparoscopic biliary exploration along with an elective laparoscopic cholecystectomy will be performed by experienced laparoscopic surgeons (over 100 laparoscopic procedures yearly) by three or four-trocar technique with transection of the cystic duct and artery.
Sponsors
Instituto Ecuatoriano de Enfermedades Digestivas
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Intervention model description
A controlled, non-inferiority prospective trial
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* Adults \>18 years old and \<89 years old * Adult symptomatic patients with gallstones documented by US * Subject is a suitable candidate for an elective laparoscopic cholecystectomy or an EUS-guided GBD * Patients or authorized representative give informed consent for endoscopic or surgical approach
Exclusion criteria
* Patients with hepato-pancreato-biliary diseases other than gallstones (tumors, obstructions, inflammation) * Patients with acute cholecystitis, cholangitis or choledocholithiasis. * Patients with gallbladder polyps, family history of gallbladder cancer, or any other high-risk factor for gallbladder cancer * Patient unable to give informed consent or refuse to participate. * Prior biliary intervention * Pregnancy or nursing * Any other medical condition that contraindicates surgical or endoscopic procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Technical success after surgical and endoscopic intervention | Up to 6 hours | Number of patients with correct placement LAMS or uneventful competition of laparoscopic cholecystectomy along with stone clearance. |
| Resolution of biliary symptoms | up to 12 months | Number of patients with clinical resolution based in a questionnaire for the assessment of biliary symptoms. |
| Adverse events after the surgical procedures | up to 14 days | The post-surgical adverse events will be assessed by the Clavien-Dindo classification |
| Adverse events after the endoscopic procedures | Up to 14 days | The post-endoscopic adverse events will be assessed by the Adverse Events Gastrointestinal Endoscopy (AGREE) Classification |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30-day major complications assessment | up to 30 days | To assess the safety of the procedures the investigators will consider the 30-day major complication rate |
| Re-intervention rate | 12-month follow-up | Number of patients that requires a re-intervention after an endoscopic or surgical procedure |
Countries
Ecuador
Contacts
Primary ContactCarlos Robles-Medranda, MD, FASGE
Outcome results
None listed